🔎 Trials Near Me

መነሻ › አኩት ማይሎይድ ሊውኬሚያ › ካንሳስ

በካንሳስ ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ 20 ጥናቶች በካንሳስ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።

በካንሳስ ውስጥ ያሉ ከተሞች

Official study text (English)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Central Care Cancer Center - Garden City, Garden City
  • Central Care Cancer Center - Great Bend, Great Bend
  • Veteran Administration Eastern Kansas Healthcare, Leavenworth
  • እና 4 ተጨማሪ
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Indian Creek Campus, Overland Park
  • እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • University of Kansas Clinical Research Center, Fairway
  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • እና 7 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Indian Creek Campus, Overland Park
  • እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Westwood Cancer Center, Westwood
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Indian Creek Campus, Overland Park
  • እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT05554406

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Kansas City KS-KUMC, Fairway
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ሴፕቴ 2026 · NCT06652438

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  • US-Kansas City KS-KUMC, Kansas City
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ሴፕቴ 2026 · NCT07223814

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Indian Creek Campus, Overland Park
  • እና 1 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT05886049

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • The University of Kansas Cancer Center, Kansas City
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT06001788

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • University of Kansas Cancer Center, Westwood
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁላይ 2026 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of Kansas, Westwood
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

  • University of Kansas Medical Center Research Institute, Inc., Kansas City
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ኤፕሪ 2026 · NCT06146257

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

  • University of Kansas Cancer Center, Westwood
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ25 ማርች 2026 · NCT03533816

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

  • University of Kansas Medical Center, Westwood
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 66 · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06859424

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • The University of Kansas Medical Center Research Institute, Fairway
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ማርች 2026 · NCT05735184

Safety of MT-401-OTS in Patients With Relapsed AML or MDS

  • KU Cancer Center, Kansas City
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 65 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ዲሴም 2025 · NCT06552416

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

  • University of Kansas, Fairway
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሜይ 2025 · NCT06634394

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

  • University of Kansas Cancer Center, Fairway
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ማርች 2025 · NCT02781883

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

  • University of Kansas Cancer Center, Fairway
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ጁን 2020 · NCT04167696

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።